Cargando…
Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
We spotlight the promising preliminary findings reported by Goldsmith et al. of a phase 1 first-in-child study showcasing the safety and efficacy of lorlatinib against treatment-refractory or relapsed ALK-driven neuroblastoma.(1)
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313925/ https://www.ncbi.nlm.nih.gov/pubmed/37343514 http://dx.doi.org/10.1016/j.xcrm.2023.101071 |
| _version_ | 1785067210326147072 |
|---|---|
| author | Suk, Yujin Singh, Sheila K. |
| author_facet | Suk, Yujin Singh, Sheila K. |
| author_sort | Suk, Yujin |
| collection | PubMed |
| description | We spotlight the promising preliminary findings reported by Goldsmith et al. of a phase 1 first-in-child study showcasing the safety and efficacy of lorlatinib against treatment-refractory or relapsed ALK-driven neuroblastoma.(1) |
| format | Online Article Text |
| id | pubmed-10313925 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103139252023-07-02 Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma Suk, Yujin Singh, Sheila K. Cell Rep Med Spotlight We spotlight the promising preliminary findings reported by Goldsmith et al. of a phase 1 first-in-child study showcasing the safety and efficacy of lorlatinib against treatment-refractory or relapsed ALK-driven neuroblastoma.(1) Elsevier 2023-06-20 /pmc/articles/PMC10313925/ /pubmed/37343514 http://dx.doi.org/10.1016/j.xcrm.2023.101071 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Spotlight Suk, Yujin Singh, Sheila K. Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma |
| title | Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma |
| title_full | Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma |
| title_fullStr | Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma |
| title_full_unstemmed | Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma |
| title_short | Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma |
| title_sort | safety and efficacy of lorlatinib against alk-driven refractory or relapsed neuroblastoma |
| topic | Spotlight |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313925/ https://www.ncbi.nlm.nih.gov/pubmed/37343514 http://dx.doi.org/10.1016/j.xcrm.2023.101071 |
| work_keys_str_mv | AT sukyujin safetyandefficacyoflorlatinibagainstalkdrivenrefractoryorrelapsedneuroblastoma AT singhsheilak safetyandefficacyoflorlatinibagainstalkdrivenrefractoryorrelapsedneuroblastoma |